Drug development in the targeted therapy era

J Clin Oncol. 2008 Aug 1;26(22):3815-6. doi: 10.1200/JCO.2008.18.2113.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Capecitabine
  • Clinical Trials, Phase II as Topic
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Disclosure
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Humans
  • Lapatinib
  • Maximum Tolerated Dose
  • Quinazolines / administration & dosage
  • Receptor, ErbB-2 / analysis

Substances

  • Quinazolines
  • Lapatinib
  • Deoxycytidine
  • Capecitabine
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Fluorouracil